Summary
15.13 -0.92(-5.70%)09/06/2024
Inhibrx Inc (INBX)
Inhibrx Inc (INBX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -5.70 | 3.88 | 27.42 | -7.09 | -57.76 | -31.44 | 0.00 | -26.68 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 15.13 | |
| Open | 16.09 | |
| High | 16.34 | |
| Low | 15.05 | |
| Volume | 112,174 | |
| Change | -0.92 | |
| Change % | -5.70 | |
| Avg Volume (20 Days) | 104,894 | |
| Volume/Avg Volume (20 Days) Ratio | 1.07 | |
| 52 Week Range | 10.80 - 39.79 | |
| Price vs 52 Week High | -61.99% | |
| Price vs 52 Week Low | 40.05% | |
| Range | -6.00 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 218 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 54.20 | |
| Book Value | 0.7430 | |
| Earnings Per Share | -2.0660 | |
| EPS Estimate Current Quarter | -0.5700 | |
| EPS Estimate Next Quarter | -0.6400 | |
| EPS Estimate Current Year | -2.1500 | |
| EPS Estimate Next Year | -2.4700 | |
| Diluted EPS (TTM) | -2.0660 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -10.3855 | |
| Return on asset (TTM) | -0.3404 | |
| Return on equity (TTM) | -1.3046 | |
| Revenue TTM | 7,151,000 | |
| Revenue per share TTM | 0.1890 | |
| Quarterly Revenue Growth (YOY) | -0.5710 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -60,607,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 52.7332 | |
| Revenue Enterprise Value | 202.9843 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 37,955,000 | |
| Shares Float | 17,500,286 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 39.91 | |
| Institutions (%) | 54.54 | |
08/13 18:54 EST - prnewswire.com
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
06/07 14:42 EST - seekingalpha.com
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
06/05 07:46 EST - benzinga.com
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
05/24 16:00 EST - prnewswire.com
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").
05/10 18:36 EST - prnewswire.com
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders, which will be held on May 24, 2024. As a result, shares of SpinCo common stock are expected to begin trading on a "when-issued" basis on Nasdaq on May 28, 2024 (rather than May 16, 2024), under the symbol "INXB" and under "Inhibrx Biosciences, Inc." When-issued trading of shares of SpinCo common stock will continue until the distribution of shares of SpinCo common stock in the Spin-Off occurs.
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders, which will be held on May 24, 2024. As a result, shares of SpinCo common stock are expected to begin trading on a "when-issued" basis on Nasdaq on May 28, 2024 (rather than May 16, 2024), under the symbol "INXB" and under "Inhibrx Biosciences, Inc." When-issued trading of shares of SpinCo common stock will continue until the distribution of shares of SpinCo common stock in the Spin-Off occurs.
05/09 15:36 EST - businesswire.com
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.
05/08 16:37 EST - prnewswire.com
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m.
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m.
02/28 11:25 EST - zacks.com
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.
02/28 09:15 EST - prnewswire.com
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024, the Company announced that it entered into a definitive agreement with Aventis, Inc. ("Aventis"), a subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all of the assets and liabilities associated with INBRX-101 ("the Merger").
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024, the Company announced that it entered into a definitive agreement with Aventis, Inc. ("Aventis"), a subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all of the assets and liabilities associated with INBRX-101 ("the Merger").
01/24 07:01 EST - zacks.com
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
01/23 15:31 EST - zacks.com
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
01/23 12:03 EST - prnewswire.com
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call Guri Ademi toll-free at 866-264-3995.
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call Guri Ademi toll-free at 866-264-3995.
01/23 11:45 EST - investopedia.com
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases.
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases.
01/23 09:33 EST - businesswire.com
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms of the proposed transaction, for each Inhibrx share, Inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets. Halp.
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms of the proposed transaction, for each Inhibrx share, Inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets. Halp.
01/23 01:00 EST - prnewswire.com
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx's outstanding debt balance and capitalize New Inhibrx with $200 million in cash SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx's outstanding debt balance and capitalize New Inhibrx with $200 million in cash SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").
11/02 09:15 EST - prnewswire.com
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Inhibrx presented this dataset as of the data cut of September 8 th, 2023 at the Annual Connective Tissue Oncology Society (CTOS) Conference today.
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Inhibrx presented this dataset as of the data cut of September 8 th, 2023 at the Annual Connective Tissue Oncology Society (CTOS) Conference today.
10/18 16:00 EST - prnewswire.com
Inhibrx Announces Participation in Upcoming Scientific Conferences
SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences: Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting November 1 st – 4th, 2023 – Dublin, Ireland Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From A Phase 1 StudyLead Author: Rashmi Chugh, MDPoster presentation on Thursday, November 2 nd, 2023 from 5:30 PM – 6:30 PM Irish Standard TimeLocation: The Liffey Convention Centre in Dublin, Ireland Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting November 3 rd – 5th, 2023 – San Diego, California Title: Phase 1/2 Study of the Bispecific 4-1BB and PD-L1 Antibody INBRX-105 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Jong Chul Park, MDAbstract: 742Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center, San Diego, CA - Hall A Presentation Title: Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Rachel E. Sanborn, MDAbstract: 748Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center in San Diego, CA - Hall A The posters will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations upon commencement of each respective presentation.
Inhibrx Announces Participation in Upcoming Scientific Conferences
SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences: Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting November 1 st – 4th, 2023 – Dublin, Ireland Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From A Phase 1 StudyLead Author: Rashmi Chugh, MDPoster presentation on Thursday, November 2 nd, 2023 from 5:30 PM – 6:30 PM Irish Standard TimeLocation: The Liffey Convention Centre in Dublin, Ireland Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting November 3 rd – 5th, 2023 – San Diego, California Title: Phase 1/2 Study of the Bispecific 4-1BB and PD-L1 Antibody INBRX-105 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Jong Chul Park, MDAbstract: 742Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center, San Diego, CA - Hall A Presentation Title: Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Rachel E. Sanborn, MDAbstract: 748Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center in San Diego, CA - Hall A The posters will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations upon commencement of each respective presentation.
09/19 16:00 EST - prnewswire.com
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD").
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD").
09/01 16:26 EST - gurufocus.com
Andreas Halvorsen's Firm Ups Inhibrx Stake
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% following a private placement financing agreement.
Andreas Halvorsen's Firm Ups Inhibrx Stake
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% following a private placement financing agreement.